Kither Biotech
- Biotech or pharma, therapeutic R&D
Kither Biotech is a clinical stage company, active in the treatment of respiratory diseases, looking for partners to co-develop its product portfolio.
Its most advanced product is KIT2014, a small peptide given by inhalation to treat Cystic Fibrosis in combination with standard of care treatments. Kither initiated a Phase 1 trial and plans to initiate a Phase 2 in patients during Q2 2024. KIT2014 is a modulator of cAMP and has the potential to treat additional pulmonary diseases, such as COPD, Bronchiectasis, Primary Cilliary Dyskinesia, etc.
The company’s product portfolio also includes KITCL27, which represents a class of PI3K inhibitors for the treatment of Idiopathic Pulmonary Fibrosis, IPF and other diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}